Vireo Growth VREOF
OTC VREOF
$10.97 -0.01 (-0.09%)
At close: Aug 19, 2026 · 3:35 PM UTC

Vireo Growth (VREOF) Cash from Investing Activities (2020 - 2026)

Vireo Growth (VREOF) posted Cash from Investing Activities of $8.0 million for Q1 2026, up 184.91% sequentially from -$9.4 million in Q4 2025, and up 827.27% YoY from $862745.1 in Q1 2025.

Vireo Growth (VREOF) Cash from Investing Activities (2020 - 2026) Analysis & Trends

Vireo Growth has reported Cash from Investing Activities for 7 years, with the latest figure at $8.0 million in Q1 2026.

  • Quarterly Cash from Investing Activities rose 827.27% year-over-year to $8.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.9 million (up 318.25% YoY) and the FY2025 annual result came in at $8.8 million, up 207.71% from the prior year.
  • Cash from Investing Activities improved to $8.0 million in Q1 2026 per VREOF's latest filing, from -$9.4 million in the prior quarter.
  • Over five years, Cash from Investing Activities peaked at $34.0 million in Q2 2025 and troughed at -$14.8 million in Q3 2025.
  • A 5-year average of -$27337.1 and a median of -$1.1 million in 2023 frame the typical range for Cash from Investing Activities.
  • The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities tumbled 1423.26% in 2024, then surged 1167.2% in 2025.
  • Over 5 years, Cash from Investing Activities stood at -$819539.0 in 2022, then jumped by 79.11% to -$171183.0 in 2023, then sank by 1423.26% to -$2.6 million in 2024, then slumped by 261.33% to -$9.4 million in 2025, then soared by 184.91% to $8.0 million in 2026.
  • According to Business Quant data, Cash from Investing Activities over the past three periods registered $8.0 million, -$9.4 million, and -$14.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Activities (Qtr)
1 Haleon 44.05 Bn 43.08 Bn - -
2 Teva Pharmaceutical Industries 43.39 Bn 39.74 Bn 2.15 Bn -491.00 Mn
3 Zoetis 31.86 Bn 30.18 Bn 1.05 Bn -300.00 Mn
4 Takeda Pharmaceutical 28.78 Bn 22.99 Bn 5.10 Bn -550.24 Mn
5 United Therapeutics 22.25 Bn 19.59 Bn 683.80 Mn 87.50 Mn
6 Viatris 18.74 Bn 17.85 Bn 1.46 Bn -51.60 Mn
7 Neurocrine Biosciences 15.58 Bn 15.19 Bn 935.80 Mn -135.40 Mn
8 Elanco Animal Health 11.92 Bn 11.39 Bn 798.00 Mn -110.00 Mn
9 Dr Reddys Laboratories 10.16 Bn 9.99 Bn - -
10 Vireo Growth 491.44 Mn 349.14 Mn 95.30 Mn -69.70 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 8.00 Mn
Mar 31, 2026 8.00 Mn
Dec 31, 2025 -9.42 Mn
Dec 31, 2025 -9.42 Mn
Sep 30, 2025 -14.76 Mn
Sep 30, 2025 -14.76 Mn
Jun 30, 2025 34.04 Mn
Jun 30, 2025 34.04 Mn
Mar 31, 2025 -1.10 Mn
Mar 31, 2025 -1.10 Mn
Dec 31, 2024 -2.61 Mn
Dec 31, 2024 -2.61 Mn
Sep 30, 2024 -1.29 Mn
Sep 30, 2024 -1.29 Mn
Jun 30, 2024 -3.19 Mn
Jun 30, 2024 -3.19 Mn
Mar 31, 2024 -1.05 Mn
Mar 31, 2024 -1.05 Mn
Dec 31, 2023 -171,183.00
Dec 31, 2023 -171,183.00